Preclinical data supports the use of IL-18 to protect NKG2D CAR T cells to improve the anti-tumor activity of the candidate product

Continue to develop second-generation multiple shRNA scaffolds for novel non-gene editing CAR T candidates with the desired phenotype

The KEYNOTE-B79 phase 1b trial evaluates CYAD-101 and KEYTRUDA ® (pembrolizumab) in the treatment of patients with microsatellite stable mCRC, which will begin in the fourth quarter of 2021

Mont Saint Gilbert, Belgium, November 12, 2021 (GLOBE NEWSWIRE) - Celyad Oncology SA (Euronext and NASDAQ: CYAD), a company specializing in the discovery and development of chimeric antigen receptor T Cell (CAR) clinical stage biotechnology company T) ​​cancer therapy, today announced three poster presentations about the company’s allogeneic CAR T therapy plan at the Society of Cancer Immunotherapy (SITC) annual meeting in Washington, DC, in fact It is November 10-14, 2021.

"Through these demonstrations, we showed how we continue to execute our strategic vision and use our non-gene editing allogeneic approach to develop a differentiated next-generation CAR T that aims to provide patients with multiple real-world benefits." Dr. Wei Gilham said. D., the chief scientific officer of Celyad Oncology. "We believe that our CAR T cells are the only allogeneic CAR T cells in human clinical trials that avoid double-stranded DNA breaks. Combining multiple shRNAs and cytokine armor, we believe that this method provides us with a A dynamic platform for generating future allogeneic candidates."

Charles Morris, MD, Chief Medical Officer of Celyad Oncology, said: "In addition to the encouraging preclinical data provided, we are also on the cusp of collaborating with MSD to initiate a phase 1b clinical trial of KEYNOTE-B79. We believe that KEYNOTE-B79 will It is the first clinical trial to evaluate allogeneic CAR T and anti-PD-1 therapies in solid tumors. We look forward to evaluating whether the expected highly complementary mechanisms of action of CYAD-101 and KEYTRUDA ® can help promote stable microsatellite diseases The important clinical benefits for patients with refractory metastatic colorectal cancer include high unmet medical needs. We look forward to launching this study in the coming weeks and providing clinical updates for the CYAD-101 program in 2022."

The main highlights of the SITC annual meeting

Poster 107-Armored NKG2D CAR T cells with IL-18 to improve anti-tumor activity in vitro and in vivo

This poster demonstrates the key role of Interleukin-18 (IL-18) in enhancing the effector function of NKG2D CAR T cells.

These data support the continuous development of the company's shRNA-based allogeneic, IL-18 armored CAR T drug candidate CYAD-203, and future allogeneic IL-18 armored CAR T drug candidates.

Poster 146-Evolution of multiple shRNAs to generate customized CAR T cell therapies

Multiplexing short hairpin RNA (shRNA) in a single vector format ensures co-expression of shRNA and therapeutic transgenes.

We continue to use multiplexing technology to develop second-generation shRNA scaffolds to produce new allogeneic clinical candidates with customized, desired phenotypes and functions that are produced using methods that avoid double-stranded DNA breaks.

Poster 407 – A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T cell CYAD-101 in patients with refractory metastatic colorectal cancer, after FOLFOX pretreatment, followed by pembrolizide anti-

The clinical and translational results of the alloSHRINK Phase 1 trial evaluated the clinical and translational results of the TCR inhibitor (TIM)-based allogeneic NKG2D CAR T cell product candidate CYAD-101 (NCT03692429) in patients with metastatic colorectal (mCRC) cancer The results indicate that sequential checkpoint suppression therapy following CYAD-101 and FOLFOX pretreatment can drive a longer-lasting clinical response.

Therefore, according to Simon's two-phase trial, the KEYNOTE-B79 trial will evaluate the safety and safety of multiple infusions of CYAD-101 after FOLFOX pretreatment chemotherapy followed by KEYTRUDA® (pembrolizumab) in the treatment of patients with microsatellite stable mCRC Clinically active design.

The KEYNOTE-B79 clinical trial is expected to begin in the fourth quarter of 2021.

These electronic posters will be available on the SITC website and the scientific publications section of the Cellyad Oncology website starting at 1:00 PM Central European Time / 7:00 AM Eastern Time today.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Kenilworth, New Jersey, USA.

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cells (CAR T) to treat cancer. The company is developing an allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidate drug for the treatment of hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is headquartered in Mount Saint Gilbert, Belgium and New York, New York. The company has received funding from the Wallonia region (Belgium) to support the advancement of its CAR T cell therapy program. For more information, please visit https://celyad.com/.

This press release may contain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements about the safety and clinical activities of the Celyad Oncology pipeline, as well as the financial status, results of operations, and business prospects. Forward-looking statements may involve known and unknown risks and uncertainties, which may cause Celyad Oncology’s actual results, financial conditions, performance or achievements to be materially different from those expressed or implied by such forward-looking statements . Such risks and uncertainties include the timetable and results of our clinical projects, including the phase 1b KEYNOTE-B79 trial, our development of other shRNA-based allogeneic drug candidates from the CYAD-200 series to clinical trials, and the duration of COVID And severity -19 pandemic and the measures taken by the government to this end. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) documents and reports, including the 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2021 Documents and reports submitted in the annual report on the form and Celyad Oncology subsequently. These forward-looking statements are only published on the date of this document, and Celyad Oncology's actual results may differ materially from the results expressed or implied in these forward-looking statements. Unless required by law or regulation, Cellyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any changes in its expectations or any changes in the events, conditions or circumstances on which any such statements are based.

Sara Zelkovic Director of Communications and Investor Relations Celyad Oncology Investors@celyad.com

Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

After obtaining positive clinical readings, Kezar Life Sciences, Inc. (NASDAQ: KZR) stock price soared on Tuesday. What happened: California-based Kezar announced positive interim results for the Phase 2 part of the MISSION clinical study, which evaluated the role of KZR-616 in patients with lupus nephritis. For the interim analysis, 5 patients have reached the end of treatment and 10 patients have reached the 13th week. At the end of the treatment period, 3 out of 5 patients had a reduction of 50% or more

Moderna Inc (NASDAQ: MRNA) announced the data of the Phase 2 (EPICCURE) study led by AstraZeneca (NASDAQ: AZN), which evaluated the effectiveness of AZD8601 in receiving coronary artery Efficacy of road transplantation (CABG) patients. AZD8601 is an mRNA therapeutic agent encoding vascular endothelial growth factor-A (VEGF-A). In the trial, 7 people received AZD8601 treatment and 4 people received placebo treatment. After six months of follow-up, the researchers concluded that the drug reached the primary endpoints of safety and tolerability, and the explosion

The dramatic increase in Medicare Part B premiums in 2022 reflects the skyrocketing price of a controversial Alzheimer's disease drug. The increase in premiums will not only weaken the newly added social security living allowance, as a result... Continue reading → Why did the post about the soaring premium of Medicare Part B in 2022 first appear on the SmartAsset blog.

A U.S. organization that reviews the value of drugs said on Tuesday that drugmakers unreasonably increased the prices of seven of the 10 most expensive prescription drugs in the U.S. in 2020, increasing drug spending by $1.67 billion. AbbVie's widely used Humira rheumatoid arthritis drug accounted for most of the increase in spending, with a net price increase of 9.6%, resulting in an increase of nearly $1.4 billion in US spending.

The company is withdrawing from early research and looking for "other opportunities" to supplement its work on cancer.

NIH disagrees with Moderna's view that who should be praised for inventing the company's COVID-19 vaccine.

Pfizer and Moderna announced actions earlier on Tuesday to support efforts to provide important drugs to low-income countries to help them fight COVID-19, ensuring antiviral treatment for the former and vaccine supply for the latter.

Pfizer said on Tuesday that it has signed a voluntary licensing agreement with the United Nations-backed public health organization Pharmaceutical Patent Pool, which will allow generic drug manufacturers to produce their oral antiviral treatments for COVID-19. This move will help expand access to this drug in low- and middle-income countries. According to the terms of the main license agreement, global qualified generic drug manufacturers with sub-licensing “will be able to provide PF-07321332 and

With the increase in COVID-19 vaccine requirements across the country, anti-vaccination sentiment in the United States has taken off.

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced updated data from the first phase of the trial, which evaluated a single intravenous infusion of RP-A501 (an investigational gene therapy for the treatment of Danone’s disease) . Danon’s disease is characterized by weakened heart muscle, weakened skeletal muscle, and mental retardation. The update includes mid-term safety and efficacy data from low-dose (6.7e13 vg/kg; n=3) and high-dose (1.1e14 vg/kg; n=2) adult and adolescent cohorts. Data demon

With age, many things will change. For some elderly people, these changes may include their bathroom habits. A report issued by the Centers for Disease Control and Prevention (CDC) in 2014 showed that 51% of adults over the age of 65 suffer from bladder or bowel incontinence-these two conditions usually cause frequent, sudden or uncontrollable Impulse to go out. “We found that half of the population had experienced urine leakage or accidental intestinal leakage, and about 25% had moderate, severe or severe

The startup’s new financing comes at a time when it is completing a clinical trial of a diagnostic test designed to detect colon cancer.

At the Bipartisan Policy Center event on Monday, Dr. Anthony Fauci said that fully vaccinated families should “feel good” about holiday gatherings.

Author: David Bautz, Ph.D. Nasdaq: OPNT Read the full OPNT research report. Financial Update On November 11, 2021, Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) announced its financial results for the third quarter of 2021 . The company reported revenue of $16.3 million for the third quarter of 2021, and revenue for the third quarter of 2020 was $9.1 million. Revenue in the third quarter of 2021

If successful, this treatment may "change the lives of many patients"

Although EU leaders have criticized the way it manufactures and supplies vaccines, AstraZeneca has become the first company in the Western world to produce 2 billion doses of Covid vaccine.

Lewy body dementia is the second most common type of dementia, but it is misunderstood and misdiagnosed. This is the brain condition and how to treat it.

The Biden government stated in a notice on Friday evening that the monthly premiums for doctors and outpatient care covering medical insurance patients will increase by 15% next year. Why it matters: Medicare people have come under fire during the election year for their sharp rise, mainly due to the problematic Alzheimer's treatment Aduhelm and the high price of uncertainty caused by the coronavirus. Learn about the latest market trends and economic insights through Axios Markets. Free subscription By

In the week ending on Sunday, Connecticut saw a surge in new coronavirus cases, with 2,781 reported, an increase of 16.6%. this...

Pre-diabetes is a serious health condition that increases the risk of type 2 diabetes, but progression to diabetes is not inevitable.